tbuckley/cabot-search huggingface dataset:
Use of gene expression analysis of periampullary carcinomas to identify biliary-like and intestinal-like subgroups of ampullary and duodenal carcinomas.
Authors: M. J. Overman, J. Zhang, G. R. Varadhachary, R. F. Hwang, M. Kapoor, J. L. Abbruzzese, R. A. Wolff, H. Wang, B. Broom
Journal: Journal of Clinical Oncology (2011)

161 Background: Though adenocarcinomas of the ampulla of Vater are classified as biliary cancers, the epithelium of origin and treatment approach for these rare tumors remains controversial. We compared the gene expression profiles of ampullary carcinomas with that of known periampullary carcinomas. Methods: We analyzed 32 fresh-frozen resected untreated periampullary carcinomas (8 pancreatic, 2 extrahepatic biliary, 8 non-ampullary duodenal, and 14 ampullary) with verified histology and &gt;70% tumor tissue using the Affymetrix U133 Plus 2.0 genome array. Hierarchical clustering of all samples based upon pancreatic and duodenal differentially expressed genes and unsupervised hierarchical clustering was done. Ampullary and duodenal samples were analyzed for histologic subtype (pancreaticobiliary, intestinal, mixed), MSI by PCR, CDX-2 by IHC and KRAS and PI3K mutations by mass spectroscopy-based sequencing (Sequenom). Results: We identified 3 subgroups: pancreatic (8 pancreatic, 1 duodenal), biliary-like (4 duodenal, 7 ampullary, 2 biliary) and intestinal-like (3 duodenal, 7 ampullary). The intestinal-like subgroup had a significantly improved RFS (p=0.03) and OS (p =0.04) compared to the biliary-like subgroup, after stratification by grade and stage. Unsupervised clustering of only ampullary and duodenal samples identified very similar good prognostic (4 duodenal, 5 ampullary) and bad prognostic groups (3 duodenal, 9 ampullary) with 3-year RFS 75% vs. 31%, p =0.05 and 3-year OS 100% vs. 27%, p =0.01. These 2 groups showed no statistically significant differences in adenoma (56% vs 25%), poor differentiation (11% vs 42%), T4 (33% vs 25%), N1 (67% vs 100%), MSI-high (22% vs 0%), KRAS mutations (33% vs 17%), or PI3K mutations (0% vs 17%). CDX-2 expression (100% vs 50%, p=.04) and intestinal histologic subtype (100% vs 0%, p &lt;0.01) were more common in the good prognostic group. Conclusions: Gene expression analysis classifies ampullary carcinomas with duodenal carcinomas and identifies a good prognosis intestinal-like group and a poor prognosis biliary-like group. These findings have therapeutic implications. [Table: see text]
Clinical Outcomes of Cord Blood Transplantation from Unrelated Donors Comparable with Marrow or Blood Transplantation from Related Donors in Adults: A Single Institute Analysis.
Authors: Satoshi Takahashi, Jun Ooi, Akira Tomonari, Takaaki Konuma, Kenji Fukuno, Nobuhiro Tsukada, Maki Monna-Ooiwa, Takuhiro Yamaguchi, Arinobu Tojo, Shigetaka Asano
Journal: Blood (2005)
Correlation of Ethnicity, Socioeconomic Status, and Co-Morbidity with Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Brian Hess, Matthew Siegel, Tulio E. Rodriguez, Shams Bakhos, Maria Theodorou, Michael Tallarico, Scott E. Smith, Aileen Go, Patrick Stiff
Journal: Blood (2012)
Repeat Treatment with Iodine-131-Rituximab Is Safe and Effective in Patients with Relapsed Indolent B-Cell Non-Hodgkin Lymphoma (NHL) Who Had Previously Responded to This Therapy.
Authors: Mark J. Bishton, Michael F. Leahy, Rod J. Hicks, J. Harvey Turner, Ad McQuillan, John Francis Seymour
Journal: Blood (2007)
REM sleep behavior disorder
Authors: E A Nofzinger, C F Reynolds
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.
Authors: Nicholas Mitsiades, Ciaran McMullan, Vassiliki Poulaki, Joseph Negri, Noopur Raje, Shaji Kumar, Despoina Sikoutri, Teru Hideshima, Dharminder Chauhan, Paul G. Richardson, Robert L. Schlossman, Andrew L. Kung, Heidi Lane, Nikhil C. Munshi, Kenneth C. Anderson, Constantine S. Mitsiades
Journal: Blood (2004)
A Case of Congenital Red Cell Pyruvate Kinase Deficiency Associated with Hereditary Spherocytosis
Authors: Cristina Vercellati, Anna Paola Maria Luisa Marcello, Elisa Fermo, Paola Bianchi, Carla Boschetti, Alessandra Iurlo, Alberto Zanella, Wilma Barcellini
Journal: Blood (2011)
Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes
Authors: Efstathios Kastritis, Ioannis Papassotiriou, Evangelos Terpos, Athanassios Akalestos, Erasmia Psimenou, Filia Apostolakou, Maria Roussou, Maria Gavriatopoulou, Elisavet Kaldara, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Constantinos Pamboucas, Evangelos Kostis, Sofoklis Kontogiannis, Savvas Th. Toumanidis, Ioannis Boletis, Meletios A. Dimopoulos
Journal: Blood (2014)
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study
Authors: Emma C Rossi, Lynn D Kowalski, Jennifer Scalici, Leigh Cantrell, Kevin Schuler, Rabbie K Hanna, Michael Method, Melissa Ade, Anastasia Ivanova, John F Boggess
Journal: The Lancet Oncology (2017)
Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia.
Authors: Bethany Tesar, Lillian Werner, Megan Hanna, Ma Reina Improgo, Nathalie Pochet, Stacey M. Fernandes, Laura Macconaill, Aviv Regev, Arnold S. Freedman, Donna S. Neuberg, Matthew L. Freedman, Jennifer R. Brown
Journal: Blood (2012)
Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies
Authors: Noelle V Frey, Anna Kalota, Melissa Potuzak, Doris Shank, Cezary R Swider, Alison Loren, Edward Stadtmauer, Alexander Perl, Adam Cuker, Barbara Konkle, Suman Sood, Steven Goldstein, Margaret Kasner, David L Porter, Selina M Luger, Alan M Gewirtz
Journal: Blood (2008)
VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information.
Authors: David Graham Oscier, Zadie Davis, Patricia Algara, Alexandra Traverse-Glehen, Kostos Stamatopoulos, Jan Delabie, Anne Gardiner, Chrysoula Belessi, Nikolaos Loutaris, Estella Matutes, Gilles Salles, Manuela Mollejo, Miguel Piris
Journal: Blood (2006)
Phase II trial of pemetrexed (P) and gemcitabine (G) as first-line chemotherapy for elderly and/or poor performance status patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
Authors: J. Blakely, F. Schnell, P. Kaywin, M. Keaton, B. Fortner, A. Epperson, L. S. Schwartzberg
Journal: Journal of Clinical Oncology (2006)

17031 Background: Pemetrexed and gemcitabine have shown to be active agents in the treatment of locally advanced or metastatic NSCLC with favorable toxicity profiles. A recent phase I study examined a biweekly schedule of P and G in combination in order to establish a maximum tolerated dose in solid tumors. (Dudeck, A. ASCO 2004 Abstract 2141.) This established the dose for this study. Methods: After informed consent all patients received biweekly cycles of P 500 mg/m 2 IV 10 minutes before G 1500 mg/m 2 IV. A maximum of 12 cycles was planned for stable or responding patients. All patients received vitamin B12 1000 μg and folic acid 1000 mg 7 days prior to the initiation of treatment and continued through treatment. Entry criteria include measurable stage IIIB/IV NSCLC by RECIST criteria, age ≥65 years and ECOG 0–2 or &lt;65 years and ECOG of 2. A total of 40 patients are scheduled to be enrolled. Primary endpoint is objective response rate. Results: To date, 19 of 29 enrolled patients have data available for analysis. The median age is 71 (range 61–85). 2 had stage IIIB and 17 stage IV, median number of sites of disease is 2. Male/Female ratio was 10/9. Performance status was as follows ECOG 0 = 3 patients, 1 = 12 patients, 2 = 4 patients. 3 patients had grade 3 or 4 neutropenia with only 1 patient having neutropenic fever. There were no grade 3 or 4 anemias or thrombocytopenias. One patient had grade 3/4 nausea; there were no other severe non-hematologic toxicities. 14 patients were evaluable for response with 3 achieving PR (21%), 10 with SD (71%) (median number of cycles 7) and 1 with PD (7%). Conclusion: Pemetrexed and gemcitabine in combination biweekly has substantial activity with a favorable toxicity profile for patients with advanced NSCLC who are elderly or have poor performance status. The study is expected to be completed and fully evaluable by ASCO. No significant financial relationships to disclose.
Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis
Authors: Mette Vesterhus, Anders Holm, Johannes Roksund Hov, Ståle Nygård, Erik Schrumpf, Espen Melum, Liv Wenche Thorbjørnsen, Vemund Paulsen, Knut Lundin, Inge Dale, Odd Helge Gilja, Serge J.L.B. Zweers, Morten Vatn, Frank G. Schaap, Peter L.M. Jansen, Thor Ueland, Helge Røsjø, Bjørn Moum, Cyriel Y. Ponsioen, Kirsten Muri Boberg, Martti Färkkilä, Tom H. Karlsen, Fridtjof Lund-Johansen
Journal: Journal of Hepatology (2017)
Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.
Authors: Iris Breitkreutz, Sonia Vallet, Marc S. Raab, Yu-Tzu Tai, Noopur Raje, Teru Hideshima, Dharminder Chauhan, Nikhil C. Munshi, Paul Richardson, Kenneth C. Anderson
Journal: Blood (2006)
Presentation Characteristics, Risk Profiles and Long-Term Outcomes in a Public Health System, Minority Patient Population with Chronic Lymphocytic Leukemia.
Authors: Sunita Nathan, Olusola Ogundipe, Perry Menini, Anshul Bamrolia, Decebal S. Griza, Tracy Smiley, Bhuvaneswari Subramanian, Ahmad Jajeh, Margaret Clare Telfer, R. Catchatourian
Journal: Blood (2006)
A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.
Authors: Eric D. Jacobsen, Ranjana H. Advani, Yasuhiro Oki, Jeff Sharman, Steven M. Horwitz, Andres Forero-Torres, Owen A. O'Connor, Andrei R. Shustov, Tanya Siddiqi, Laurie E. Grove, Nancy L. Bartlett
Journal: Blood (2012)
Abstract B39: PI3K therapy-induced adaptive mitochondria reprogramming fuels metastatic traits
Authors: M. Cecilia Caino, Dario C. Altieri
Journal: Cancer Research (2016)

Abstract Tumors rewire cell metabolism and autophagy to adapt to environmental stress conditions, including hypoxia, starvation and oxidative stress. Such adaptive reprogramming includes a switch from oxidative phosphorylation to glycolysis, use of glutamine as fuel instead of glucose and increased biosynthesis of lipids and nucleotides. Although these processes promote resistance to apoptosis and support biomass expansion, they are also energetically inefficient, making it unclear how transformed cells accomplish highly energy-demanding tasks, including invasion and metastasis. Scattered evidences suggest that mitochondrial oxidative phosphorylation may be important for cancer traits, including stemmness, tumor repopulation and drug resistance. We recently demonstrated that targeting of the universal cancer node phosphatidylinositol-3 kinase (PI3K) induces extensive bioenergetics and transcriptional reprogramming in tumor cells, paradoxically culminating with preservation of homeostatic mitochondrial bioenergetics, opposing permeability transition and tumor cell death. Here we sought to understand how tumors adapt to molecular therapy as it pertains to tumor progression. Our results show that PI3K inhibitors used in the clinic induce global changes in activation of growth factor receptor kinases, reactivation of Akt and mTOR signaling, and dramatically increased tumor cell invasion. This involves the trafficking of energetically active mitochondria to the cortical cytoskeleton of tumor cells, supporting membrane lamellipodia dynamics, heightened turnover of focal adhesion complexes and increased velocity and distance of random cell migration. Furthermore, a single dose of PI3Ki increased liver metastasis after intrasplenic-injection of tumor cells in mice. Mechanistic studies pinpoint the role of Akt, mTOR, mitochondrial Hsp90s, the autophagy initiating complex ULK1/FIP200 and focal adhesion kinase (FAK) in the adaptive response to PI3Ki. Blocking oxidative phosphorylation by targeting mtHsp90s prevented the repositioning of mitochondria to sites of cell movements, impaired membrane dynamics and suppressed tumor cell invasion. Our results suggest a potential drawback for PI3K therapy, namely the increased risk of metastasis in patients. Targeting mitochondrial reprogramming is feasible, and could provide a novel therapeutic strategy to limit disease dissemination. Note: This abstract was not presented at the conference. Citation Format: M. Cecilia Caino, Dario C. Altieri. PI3K therapy-induced adaptive mitochondria reprogramming fuels metastatic traits. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr B39.
ADAMTS13 Antigen Levels and the Risk of Relapse during Long-Term Clinical Follow Up of Patients with Idiopathic Thrombotic Thrombocytopenic Purpura.
Authors: Spero R. Cataland, Ming Jin, Shili Lin, Melanie Kennedy, Eric H. Kraut, James N. George, Haifeng M. Wu
Journal: Blood (2007)
Abstract A19: Silencing LEF1 decreases the resistance of colorectal cancer cell lines to 5-FU as common chemotherapeutic drug
Authors: Ladan Teimoori-Toolabi, Elham Fakhr, Fatemeh Zare
Journal: Cancer Research (2017)

Abstract Wnt signaling pathway is assumed to be the most important pathway activated in colorectal cancer. As this pathway in addition to Notch and hedgehog signaling pathway is responsible for the maintenance of stem cells in the population of cancerous cells, it could be predicted that by silencing this pathway the resistance of cancerous cells to chemotherapeutic drugs would be decreased. In this regard we tried to silence LEF1 as an important component of this pathway in two colorectal cancer cell lines and see the response of transfected cells to 5-flurouracil. Oligonucleotide for silencing LEF1 was constructed and inserted into pSilencer Neo2.1 (Invitrogen). Thereafter these constructed were stably transfected to HCT116 and SW480 as colorectal cancer cell lines after treating the transfected cells with G418 for 21 days. Response of these cells to 5-flurouracil as a common chemotherapeutic drug was studied by MTT proliferation assay. The expression of LEF1 in transfected and non-transfected cells was also studied by Quantitative PCR. Cell cycle analysis was done by staining the cells with PI and analyzing them by flowcytometry instrument. While the expression of LEF1 in SW480 transfected with pSilencer-antiLEF1 reduced to 0.004 in comparison to non-transfected cells in HCT116 cells transfected with pSilencer-anti LEF1 this value was 0.000002 in comparison to non-transfected cells. Whereas the LC50 of 5-Flurouracil on non-transfected HCT116 and SW480 for 5-FU were 0.55 ng/µl and 1.45 ng/µl respectively. These values in transfected cells reduced to 0.18 and 0.1 ng/µl respectively. The percentages of proliferating cells (G2+S) stably transfected cells reduced to 30% and 32% in comparison to 39% and 45% in SW480 and HCT116 cell lines respectively. These findings showed that silencing LEF1 as a main component of wnt signaling pathway sensitizes HCT116 and SW480 cells to 5-flurouracil. The difference between sensitizing strength may be due to mutations in other components of wnt signaling pathway or mutations in other genes like p53 and k-ras which is dissimilar between HCT116 and SW480 cells. This modality can be considered as sensitizing agents adjuvant to other chemotherapeutic drugs like 5-FU. Note: This abstract was not presented at the conference. Citation Format: Ladan Teimoori-Toolabi, Elham Fakhr, Fatemeh Zare. Silencing LEF1 decreases the resistance of colorectal cancer cell lines to 5-FU as common chemotherapeutic drug. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr A19.
Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
Authors: Lennart Tonneijck, Marcel H.A. Muskiet, Mark M. Smits, Erik J. van Bommel, Hiddo J.L. Heerspink, Daniël H. van Raalte, Jaap A. Joles
Journal: Journal of the American Society of Nephrology (2017)

An absolute, supraphysiologic elevation in GFR is observed early in the natural history in 10%–67% and 6%–73% of patients with type 1 and type 2 diabetes, respectively. Moreover, at the single-nephron level, diabetes-related renal hemodynamic alterations—as an adaptation to reduction in functional nephron mass and/or in response to prevailing metabolic and (neuro)hormonal stimuli—increase glomerular hydraulic pressure and transcapillary convective flux of ultrafiltrate and macromolecules. This phenomenon, known as glomerular hyperfiltration, classically has been hypothesized to predispose to irreversible nephron damage, thereby contributing to initiation and progression of kidney disease in diabetes. However, dedicated studies with appropriate diagnostic measures and clinically relevant end points are warranted to confirm this assumption. In this review, we summarize the hitherto proposed mechanisms involved in diabetic hyperfiltration, focusing on ultrastructural, vascular, and tubular factors. Furthermore, we review available evidence on the clinical significance of hyperfiltration in diabetes and discuss currently available and emerging interventions that may attenuate this renal hemodynamic abnormality. The revived interest in glomerular hyperfiltration as a prognostic and pathophysiologic factor in diabetes may lead to improved and timely detection of (progressive) kidney disease, and could provide new therapeutic opportunities in alleviating the renal burden in this population.
Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting
Authors: Meena P. Rao, Sana M. Al-Khatib, Sean D. Pokorney, Lilin She, Alexander Romanov, Jose C. Nicolau, Kerry L. Lee, Peter Carson, Craig H. Selzman, Janina Stepinska, John G.F. Cleland, Wiwun Tungsubutra, Patrice M. Desvigne-Nickens, Carla A. Sueta, Matthias Siepe, Irene Lang, Arthur M. Feldman, Michael Yii, Jean L. Rouleau, Eric J. Velazquez
Journal: Circulation (2017)

Background: The risk of sudden cardiac death (SCD) in patients with heart failure after coronary artery bypass graft surgery (CABG) has not been examined in a contemporary clinical trial of surgical revascularization. This analysis describes the incidence, timing, and clinical predictors of SCD after CABG. Methods: Patients enrolled in the STICH trial (Surgical Treatment of Ischemic Heart Failure) who underwent CABG with or without surgical ventricular reconstruction were included. We excluded patients with prior implantable cardioverter-defibrillator and those randomized only to medical therapy. The primary outcome was SCD as adjudicated by a blinded committee. A Cox model was used to examine and identify predictors of SCD. The Fine and Gray method was used to estimate the incidence of SCD accounting for the competing risk of other deaths. Results: Over a median follow-up of 46 months, 113 of 1411 patients who received CABG without (n = 934) or with (n = 477) surgical ventricular reconstruction had SCD; 311 died of other causes. The mean left ventricular ejection fraction at enrollment was 28±9%. The 5-year cumulative incidence of SCD was 8.5%. Patients who had SCD and those who did not die were younger and had fewer comorbid conditions than did those who died of causes other than SCD. In the first 30 days after CABG, SCD (n=5) accounted for 7% of all deaths. The numerically greatest monthly rate of SCD was in the 31- to 90-day time period. In a multivariable analysis including baseline demographics, risk factors, coronary anatomy, and left ventricular function, end-systolic volume index and B-type natriuretic peptide were most strongly associated with SCD. Conclusions: The monthly risk of SCD shortly after CABG among patients with a low left ventricular ejection fraction is highest between the first and third months, suggesting that risk stratification for SCD should occur early in the postoperative period, particularly in patients with increased preoperative end-systolic volume index or B-type natriuretic peptide. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT0002359.
The Tibetan PHD2 Polymorphism Asp4Glu Is Associated with Hypersensitivity of Erythroid Progenitors to EPO and Upregulation of HIF-1 Regulated Genes Hexokinase (HK1) and Glucose Transporter 1 (SLC2A/GLUT1),
Authors: Felipe R Lorenzo, Sabina Swierczek, Chad Daniel Huff, Josef T. Prchal
Journal: Blood (2011)
Incidence of Neutropenia and Hypogammaglobulinemia and Correlation with the Infections Rate in Indolent Non-Hodgkin Lymphoma (NHL) Receiving Rituximab Maintenance.
Authors: Ana Marin-Niebla, Eduardo Rios-Herranz, Jose F. Falantes, Mariluz Martino, Ildefonso Espigado, Alvaro Urbano-Ispizua
Journal: Blood (2007)
Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL
Authors: Ralf C Bargou, Peter Kufer, Mariele Goebeler, Stefan Knop, Hermann Einsele, Richard Noppeney, Andreas Viardot, Patrick A Baeuerle, Carsten Reinhardt, Margit Schmidt, Petra Klappers, Dirk Nagorsen, Gerhard Zugmaier
Journal: Blood (2008)
Outcome of Acute Promyelocytic Leukemia (APL) with Very High WBC Counts Treated with ATRA and Chemotherapy (CT): The European Group Experience.
Authors: C. Kelaidi, S. Chevret, S. de Botton, E. Raffoux, A. Guerci, X. Thomas, C. Gardin, A. Pigneux, A. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, S. Meyer-Monard, R. Chelo, T. Pabst, P. Chevalier, F. Maloisel, E. Deconinck, A. Ferrant, D. Bron, N. Fegueux, J. de la Serna, G. Martin, J. Cahn, N. Ifrah, B. Cassinat, H. Dombret, M.A. Sanz, Pierre Fenaux, L. Ades
Journal: Blood (2007)
Evaluation of a VENOus-Return Assist Device (Venowave™) To Treat Severe Post-Thrombotic Syndrome (VENOPTS): A Randomized Controlled Trial.
Authors: Martin O’Donnell, Simon McRae, Susan Kahn, Jim Julian, Clive Kearon, Betsy MacKinnon, Debbie Magier, Carla Strulovitch, Theresa Lyons, Jack Hirsh, Jeffrey Ginsberg
Journal: Blood (2006)